Raily Aesthetic Medicine International Holdings Ltd. has announced a significant transaction involving a reduction in its equity interest in a subsidiary, the Target Company, from 100% to 30%. This comes as a result of an Investment Agreement entered into by Hangzhou Raily, a wholly-owned subsidiary of Raily Aesthetic, and two investors. The transaction involves a capital injection of RMB5,005,000 by the investors and a capital reduction of RMB2,855,000 by Hangzhou Raily. Following the completion of the transaction, the Target Company will be owned 10% by the First Investor, 60% by the Second Investor, and 30% by Hangzhou Raily. The transaction is expected to result in a gain of RMB528,000 and is anticipated to have a positive financial impact on Raily Aesthetic Medicine International Holdings Ltd. The company believes that the terms of the transaction are fair and beneficial for its future prospects and overall interests.